Genzyme's Lumizyme finally wins FDA nod for late-onset Pompe disease
This article was originally published in Scrip
Executive Summary
The US FDA has approved Genzyme's Lumizyme (alglucosidase alfa) for the treatment of late-onset Pompe disease. The approval includes a restricted distribution programme under a risk evaluation and mitigation strategy (REMS) and postmarketing study requirements.